2026年医疗与生命科学领域核心趋势报告_36页_9mb

2026 Health Care & Life Sciences Top Trends Summary

Core Content

The 2026 Health Care & Life Sciences Top Trends report from Foley & Lardner LLP outlines the most pressing developments shaping the industry. It highlights a regulatory and enforcement environment that is increasingly focused on compliance, transparency, and accountability. Key areas of concern include antitrust issues, AI and digital health, Medicare Advantage (MA) audits, and cybersecurity threats. The report also discusses the impact of policy changes and the growing scrutiny of remote monitoring and genetic testing practices.

Main Trends and Key Points

1. Enforcement-Led Environment

• Federal Oversight: President Trump's second term continues to prioritize health care enforcement, especially under the False Claims Act (FCA).
• DOJ Actions: The DOJ announced a White-Collar Enforcement Plan in May 2025, with health care fraud as a top priority. This includes the creation of a Health Care Fraud Data Fusion Center to enhance detection and prosecution.
• False Claims Act Working Group: A new initiative was launched to improve interagency coordination and target areas like Medicare Advantage, drug pricing, network adequacy, and kickbacks.

2. Remote Monitoring Enforcement

• Regulatory Scrutiny: Remote monitoring services such as RPM, RTM, CCM, PCM, and TCM are under intense regulatory review.
• OIG Alerts: The OIG issued warnings in 2023 and 2024 about misleading enrollment, improper billing, and lack of patient-provider interaction.
• Enforcement Actions:
  • LiveCare Inc. paid $4.9 million for alleged violations of the Anti-Kickback Statute and FCA.
  • Health Wealth Safe, Inc. settled for $1.29 million for using unapproved devices and non-compliant billing.
  • Capital Health System, Inc. paid $528,937.50 for submitting non-compliant RPM claims.
• Compliance Recommendations:
  • Ensure proper documentation, accurate billing, and ethical enrollment.
  • Review licensure and supervision, state practice standards, real-time communication requirements, and time-based coding.
  • Implement fraud and abuse controls and device-related compliance.

3. Medicare Advantage (MA) and Risk Adjustment Audits

• RADV Audit Overhaul: CMS expanded its Risk Adjustment Data Validation (RADV) audit program to include all eligible MA contracts annually, with a focus on statistical extrapolation to estimate overpayments.
• Estimated Overpayment: CMS estimated potential overpayment could reach $43 billion annually, but this authority was temporarily halted due to a court ruling.
• OIG Involvement: The OIG is intensifying oversight of diagnosis coding accuracy and has issued reports showing significant compliance gaps in RPM services.
• Dual Enforcement Risk: MA plans and providers face increased scrutiny from both CMS and OIG, requiring robust compliance and operational readiness.

4. Digital Health and AI Regulation

• Regulatory Uncertainty: AI-generated data in health care is a growing concern, with the USPTO yet to issue clear guidance.
• AI in Diagnostics: The role of AI in diagnostics and therapeutics inventions is under examination, and companies must prepare for potential patent challenges.
• Data Privacy and Security: The legal environment is evolving, emphasizing the need for data governance and privacy compliance.

5. Antitrust Enforcement

• Algorithmic Pricing: The use of algorithmic pricing software is under antitrust scrutiny, with the DOJ arguing that common algorithms can constitute concerted action under the Sherman Act.
• Pharmaceutical Pricing: PBMs and drug pricing practices are being closely monitored, including allegations of insulin price inflation.
• Orange Book Patents: The FTC is actively challenging improper patent listings in the FDA's Orange Book, especially for drug-device combinations, to prevent monopolization and delay of generic entry.
• Compliance Actions: Companies should review rebate and product bundling practices, drug-device patent listings, and labor policies to mitigate antitrust risks.

6. Medicaid and Medicare Cuts

• Medicaid Spending Reduction: President Trump signed H.R. 1 (One Big Beautiful Bill Act) in 2025, reducing federal Medicaid spending by $900 billion over 10 years.
• Impact on Providers: Safety net providers must prepare for federal budget cuts, which may lead to reduced reimbursements and increased financial pressure.

7. GLP-1 Drugs and Medical Devices

• Market Growth: The GLP-1 market is experiencing momentum, but with tighter regulatory guardrails.
• FDA Oversight: The FDA is issuing warning letters for unapproved compounded GLP-1 products.
• Payment Changes: CMS will pay for skin substitutes under the Physician Fee Schedule (PFS) as incident-to supplies, reducing Medicare spending by nearly 90%.
• Cybersecurity Concerns: Medical devices like smart watches and wearables are ripe targets for cybercriminals, requiring enhanced security measures.

8. Legal and Compliance Imperatives

• Proactive Compliance: Organizations must proactively assess risks, maintain thorough documentation, and ensure billing practices are defensible.
• Operational Resilience: Investment in compliance, data governance, operational readiness, and strategic technology deployment is essential to navigate the uncertain regulatory landscape.

Conclusion

The 2026 health care and life sciences landscape is marked by intense regulatory and enforcement activity, driven by technological advancements, policy shifts, and increased scrutiny of fraud and abuse. The report emphasizes that innovation must be balanced with accountability, and that compliance programs, data governance, and strategic risk management will be critical for success. Organizations must remain vigilant and prepared to adapt to the evolving legal and regulatory environment.